Neurocrine Biosciences (NBIX) Research & Development (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Research & Development of $326.7 million for Q2 2026, up 33.73% year-over-year from $244.3 million in Q2 2025, and up 1352.0% on a QoQ basis from $22.5 million in Q1 2026.
Neurocrine Biosciences (NBIX) Research & Development (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Research & Development for 17 years, with the latest figure at $326.7 million in Q2 2026.
- Research & Development for Q2 2026 came in at $326.7 million, up 33.73% year-over-year; the trailing twelve-month figure through Jun 2026 was $857.4 million (up 29.44% YoY), and the FY2025 annual result was $1.0 billion, up 38.93% from the prior year.
- Research & Development climbed to $326.7 million in Q2 2026, from $22.5 million in the prior quarter.
- Over five years, Research & Development peaked at $326.7 million in Q2 2026 and troughed at $5.0 million in Q1 2024.
- A 5-year average of $131.5 million and a median of $138.5 million in 2023 frame the typical range for Research & Development.
- The widest annual swing landed in 2023, when Research & Development jumped 1810.96%; it then sank 96.42% in 2024.
- A 5-year view of Research & Development shows it stood at $118.0 million in 2022, then increased by 16.53% to $137.5 million in 2023, then soared by 34.98% to $185.6 million in 2024, then soared by 39.12% to $258.2 million in 2025, then advanced by 26.53% to $326.7 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $326.7 million in Q2 2026, $22.5 million in Q1 2026, and $258.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | 154.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 326.70 Mn |
| Mar 31, 2026 | 296.20 Mn |
| Dec 31, 2025 | 258.20 Mn |
| Sep 30, 2025 | 250.00 Mn |
| Jun 30, 2025 | 15.00 Mn |
| Mar 31, 2025 | 263.20 Mn |
| Dec 31, 2024 | 185.60 Mn |
| Sep 30, 2024 | 195.00 Mn |
| Jun 30, 2024 | 7.50 Mn |
| Mar 31, 2024 | 5.00 Mn |
| Dec 31, 2023 | 137.50 Mn |
| Sep 30, 2023 | 142.20 Mn |
| Jun 30, 2023 | 145.80 Mn |
| Mar 31, 2023 | 139.50 Mn |
| Dec 31, 2022 | 118.00 Mn |
| Sep 30, 2022 | 107.70 Mn |
| Jun 30, 2022 | 30.00 Mn |
| Mar 31, 2022 | 7.30 Mn |
| Dec 31, 2021 | 87.40 Mn |
| Sep 30, 2021 | 92.70 Mn |